Search Bar & Filters
Found 28 Actively Recruiting clinical trials
Actively Recruiting
This research aims to screen for pancreatic cancer and its early signs in people aged 50 and older who have a strong family history or genetic risk for pancreatic cancer. The study focuses on using Magnetic Resonance Imaging and Magnetic cholangiopancreatography MRIMRCP to detect early-stage pancreatic cancer or precursor lesions. Blood samples will also be collected to help develop a blood-based screening test for pancreatic cancer. Participants will undergo annual MRIMRCP with IV gadolinium contrast and high-resolution imaging of the pancreas for up to 3 years, totaling four scans. Blood samples and a brief psychological survey will be collected every six months during this period. If any abnormalities appear on MRI, these will be reviewed by a multi-disciplinary tumor board and discussed with the participant. The study covers all MRI costs. Throughout the study, participants will be asked to complete surveys and provide blood samples for a bio-bank. The research team will monitor findings from MRI scans and blood tests regularly to detect early pancreatic cancer or precursor lesions. The study lasts up to three years and includes ongoing assessments to ensure participants health and safety during this time.
Actively Recruiting
Healthy Volunteer
This research aims to explore the link between new-onset or worsening diabetes and the later development of pancreatic cancer. It focuses on individuals over 50 years old who have either been diagnosed with diabetes within the past year or have experienced deteriorating diabetes recently. The study uses Magnetic Resonance Imaging and Magnetic Cholangiopancreatography MRIMRCP to screen for early pancreatic cancer or its precursors, helping to identify risks earlier. Participants will undergo an MRI with contrast at the start of the study. Any abnormalities found will be reviewed by a team of specialists and discussed with the participant. Blood samples will be collected every six months for up to three years to create a bio-bank that supports developing a blood test for pancreatic cancer. Additional MRI scans may be done as needed based on expert recommendations. During the study, participants will complete a brief psychological survey and provide blood samples regularly. Researchers will monitor the presence of early pancreatic cancer or precursor lesions over three years. The study tracks the relative risk of pancreatic cancer among those with new or worsening diabetes. Participants must be willing to undergo MRI screening, provide informed consent, and attend all study visits during this period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.
Actively Recruiting
Researchers are evaluating the safety and effects of the medicine Mevrometostat for treating RelapsedRefractory Small Cell Lung Cancer SCLC, Castration Resistant Prostate Cancer CRPC, and Follicular Lymphoma FL. This Phase 1 open-label study includes three parts, with Parts 1 and 2 closed for enrollment. Part 3, currently open, focuses on men with CRPC who have progressed after prior treatment. The study aims to understand how the study medicine behaves in the body and its impact on cancer. Participants in Part 3 receive Mevrometostat andor Enzalutamide. The study has two substudies a Bioequivalence BE substudy comparing two formulations of Mevrometostat, and a Drug-Drug Interaction DDI substudy with two cohorts. The BE substudy involves three single doses of Mevrometostat. The DDI substudy Cohort 1 takes Mevrometostat andor Itraconazole, and Cohort 2 combines Mevrometostat, Enzalutamide, and Itraconazole. After assessment phases, participants enter maintenance, taking Mevrometostat twice daily and Enzalutamide once daily until disease progression. Participants will visit the study center for dosing and monitoring, including evaluations of side effects, blood tests, and disease progression. The study measures dose-limiting toxicities, overall safety, and preliminary effectiveness using disease-specific criteria. Pharmacokinetics and patient-reported outcomes are also assessed at specific times. The study lasts approximately two years after the first participants visit, aiming to provide detailed safety and efficacy information.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of neoadjuvant carboplatin combined with mirvetuximab soravtansine in adult women with advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer that expresses folate receptor alpha FR. This phase 2, single-arm study focuses on patients with stage III or IV disease confirmed by specific diagnostic criteria. Mirvetuximab soravtansine is an investigational antibody drug conjugate designed to selectively target and kill cancer cells expressing FR. Participants receive intravenous infusions of mirvetuximab soravtansine together with carboplatin on day 1 of each 21-day cycle, for up to 6 to 9 cycles. Bevacizumab may also be given at the investigators discretion. The treatment is provided in a hospital or clinic setting. The total study duration, including treatment and follow-up, is approximately three years. During the study, participants attend regular visits for medical assessments, blood tests, and imaging scans to monitor their condition and treatment response. Researchers will evaluate the objective response to treatment by independent central review and investigator assessments, as well as safety through adverse event monitoring. Additional measures include progression-free survival, disease control, symptom changes, and surgery outcomes. The study aims to understand how well the treatment works and its safety profile over the course of the trial.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of plixorafenib in participants with cancers that have specific BRAF gene alterations. These include locally advanced or metastatic solid tumors, primary central nervous system tumors, and rare BRAF V600E-mutated solid tumors such as anaplastic thyroid, ovarian, and cholangiocarcinoma cancers. The study focuses on participants with BRAF V600E mutations or BRAF fusions and seeks to understand treatment effects across various cancer types. Participants receive plixorafenib orally in continuous 3-week cycles. Dosing may be increased as tolerated and continues until disease progression, unacceptable side effects, or withdrawal for other reasons. The study includes different subprotocols tailored to tumor type and BRAF alteration, such as unresectable solid tumors with BRAF fusions, recurrent primary CNS tumors with BRAF V600E mutations, rare non-CNS solid tumors with BRAF V600E mutations, and other advanced solid tumors with BRAF V600E mutations. Participants will undergo scans before starting treatment to assess tumor changes, and regular monitoring will continue during treatment. Researchers will evaluate tumor response, progression-free survival, overall survival, treatment safety, and drug levels in the blood over up to approximately four years. The study tracks side effects and collects detailed pharmacokinetic data to understand how the drug is processed. Participants remain in the study until disease progression or other withdrawal criteria are met, with ongoing safety and efficacy assessments.
Actively Recruiting
Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.
Actively Recruiting
Researchers are evaluating the effectiveness of the Change4Better C4B mobile app in reducing the severity of problem gambling compared to standard treatment as usual TAU. This study is a 6-month randomized clinical trial involving individuals with gambling disorder who are enrolled in or seeking treatment at outpatient facilities affiliated with Bettor Choice Gambling Treatment Programs or Kindbridge Behavioral Health. The study aims to assess the feasibility and efficacy of adding the C4B app, which is based on cognitive behavioral therapy, as a support tool alongside routine outpatient treatment. Participants will be randomly assigned to one of two groups one group will receive standard TAU, which includes individual or group therapy sessions tailored to their needs and usually lasts about one hour per week for 12 weeks. The other group will receive TAU plus access to the C4B mobile app, which teaches skills to manage gambling behaviors and cognitive distortions. Participants using the app will be instructed by staff on how to use it and encouraged to spend about 8 hours over 12 weeks completing modules and practicing exercises. Monthly follow-up continues for an additional 12 weeks, during which the app remains accessible. During the study, participants will be monitored for changes in gambling symptom severity from baseline to 6 months. Researchers will track app engagement through measures such as days used, topics completed, practice exercises, weekly usage, and total time spent. Participants will continue receiving usual outpatient care, and data will be collected through assessments and follow-ups conducted by the Yale research team. The total study duration for each participant is 6 months, starting from randomization.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
1-10 of 28
1